Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy-Reference-Cited by-同舟云学术

Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy

Published:2012-05-14 Issue:7 Volume:131 Page:E1100-E1108
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Butkiewicz Dorota,Drosik Anna,Suwiński Rafał,Krześniak Małgorzata,Rusin Marek,Kosarewicz Agata,Rachtan Jadwiga,Matuszczyk Iwona,Gawkowska-Suwińska Marzena

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference43 articles.

1. Molecular mechanisms of resistance and toxicity associated with platinating agents;Rabik;Cancer Treat Rev,2007

2. Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis;Guo;Radiat Res,2005

3. Genome maintenance mechanisms for preventing cancer;Hoeijmakers;Nature,2001

4. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer;Zienolddiny;Carcinogenesis,2006

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Rho guanine nucleotide exchange factors in non-small cell lung cancer;Bioengineered;2021-12-02

2. Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis;BioMed Research International;2020-10-22

3. The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy;Frontiers in Pharmacology;2020-07-21

4. XPA: DNA Repair Protein of Significant Clinical Importance;International Journal of Molecular Sciences;2020-03-22

5. Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial;International Journal of Cancer;2019-05-31